Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Wearing Off Effect”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Post-approval studies (Phase 4)Study completedNCT04821687
What this trial is testing

Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

Who this might be right for
Parkinson Disease
SK Chemicals Co., Ltd. 169
Large-scale testing (Phase 3)Study completedNCT00200512
What this trial is testing

Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months

Who this might be right for
Parkinson Disease
Mylan Bertek Pharmaceuticals 16
Large-scale testing (Phase 3)Study completedNCT00200525
What this trial is testing

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

Who this might be right for
Parkinson Disease
Mylan Bertek Pharmaceuticals 60
Not applicableStudy completedNCT03792204
What this trial is testing

The Prevalence of "Wearing-off" in Patients With Parkinson's Disease in Shanghai

Who this might be right for
Wearing Off EffectParkinson Disease
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 1,480
Post-approval studies (Phase 4)WithdrawnNCT00601978
What this trial is testing

Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

Who this might be right for
Parkinson's Disease
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT00562198
What this trial is testing

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding

Who this might be right for
Parkinson´s Disease
Orion Corporation, Orion Pharma 16
Not applicableStudy completedNCT05627271
What this trial is testing

The 'Wearing Off' Effect of DMT

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 39
Large-scale testing (Phase 3)Study completedNCT00700869
What this trial is testing

Evaluation of a New Mechanical Ventilation Weaning Strategy for Patients With Altered Level of Consciousness

Who this might be right for
Artificial RespirationConsciousness DisordersWearing Off Effect
Assistance Publique - Hôpitaux de Paris 34
Post-approval studies (Phase 4)Study completedNCT04990284
What this trial is testing

EArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.

Who this might be right for
Parkinson Disease
Bial - Portela C S.A. 106
Post-approval studies (Phase 4)Study completedNCT00219284
What this trial is testing

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

Who this might be right for
Parkinson's Disease With End of Dose Wearing Off
Novartis Pharmaceuticals 359
Not applicableStudy completedNCT04478591
What this trial is testing

The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Amsterdam UMC, location VUmc 117
Not applicableStudy completedNCT06121349
What this trial is testing

WOE of Anti-CD20 Therapies

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 157
Large-scale testing (Phase 3)Study completedNCT00142545
What this trial is testing

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

Who this might be right for
Parkinson Disease
Mylan Bertek Pharmaceuticals 800
Post-approval studies (Phase 4)Ended earlyNCT00642356
What this trial is testing

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

Who this might be right for
Parkinson's Disease
Novartis 14